Enamine
Private Company
Funding information not available
Overview
Enamine operates as a hybrid chemical supplier and drug discovery CRO, uniquely positioned at the intersection of physical chemistry and computational design. It maintains the world's largest in-stock collection of building blocks (over 300,000 compounds) and offers access to trillions of make-on-demand compounds through its Enamine REAL virtual space. The company is increasingly focused on integrating advanced AI/ML modeling and participating in high-profile open-science collaborations to drive next-generation drug discovery, particularly in challenging target areas. Its business model is built on a combination of product sales, custom synthesis services, and collaborative R&D partnerships.
Technology Platform
Integrated platform combining the world's largest physical/virtual chemical library (Enamine REAL, >30 trillion compounds) with advanced CADD/AI modeling, custom synthesis, and FTE chemistry services to accelerate early drug discovery.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Enamine is the dominant player in chemical building blocks and make-on-demand compounds, competing with large suppliers (e.g., Merck MilliporeSigma) and full-service CROs (e.g., WuXi AppTec, Evotec). Its key differentiator is the unparalleled scale and accessibility of its REAL chemical space, combined with strong internal synthesis capacity, making it a preferred partner for large-scale virtual screening and AI-based discovery projects.